SBRT group | Within group | 3DCRT group | Within group | Differences between groups | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
n | Median | IQR | p-value | n | Median | IQR | HL | 95% CI | p-value | ||
All metastases | |||||||||||
HU Baseline | 27 | 219.0 | 141.0–364.0 | 28 | 248.0 | 155.0–307.0 | −11 | −66.0-55.0 | 0.762 | ||
HU T2 | 23 | 231.0 | 196.0–420.0 | 23 | 310.0 | 234.0–428.0 | −29 | −100.0-63.0 | 0.455 | ||
HU T3 | 18 | 336.5 | 215.0–481 | 20 | 363.5 | 218.5–463.5 | −2.5 | − 117.0-105.0 | 0.942 | ||
3 months | |||||||||||
HU T0-T2 | 23 | 65.0 | 22.0–107.0 | < 0.01 | 23 | 64.0 | 16.0–108.0 | < 0.01 | 5.0 | −40.0-52.0 | 0.860 |
HU T0-T2 (%) | 23 | 33.8 | 12.0–69.6 | < 0.01 | 23 | 32.9 | 5.3–48.1 | < 0.01 | 5.4 | −17.6-30.0 | 0.629 |
6 months | |||||||||||
HU T0-T3 | 18 | 95.0 | 50.0–208.0 | < 0.01 | 20 | 97.5 | 59.5–158.0 | < 0.01 | 19.5 | −50.0-106.0 | 0.714 |
HU T0-T3 (%) | 18 | 72.1 | 15.2–95.7 | < 0.01 | 20 | 41.2 | 18.9–55.0 | < 0.01 | 29.2 | −21.4-58.4 | 0.327 |
Subgroup analysis | |||||||||||
Osteolyltic metastases | |||||||||||
HU Baseline | 8 | 164.0 | 116.0–240.0 | 4 | 149.0 | 127.0–248.0 | −0.5 | − 147.0-197.0 | 1.000 | ||
HU T2 | 6 | 234.0 | 156.0–480 | 4 | 219.0 | 181.0–503.0 | 23.5 | −334.0-616.0 | 0.749 | ||
HU T3 | 6 | 312.5 | 200.0–481.0 | 3 | 222.0 | 204.0–794 | 14.5 | − 351.0-614.0 | 0.699 | ||
3 months | |||||||||||
HU T0-T2 | 6 | 69.5 | 64.0–133.0 | 0.031 | 4 | 70.0 | 54.0–255.0 | 0.125 | 1.0 | −213.0-370.0 | 1.000 |
HU T0-T2 (%) | 6 | 53.9 | 33.8–86.7 | 0.031 | 4 | 46.9 | 42.2–88.3 | 0.125 | 8.6 | −60.4-94.6 | 0.594 |
6 months | |||||||||||
HU T0-T3 | 6 | 165.5 | 88.0–208.0 | 0.031 | 3 | 64.0 | 64.0–456.0 | 0.250 | −24.0 | − 156.0-396.0 | 0.899 |
HU T0-T3 (%) | 6 | 85.8 | 59.9–95.7 | 0.031 | 3 | 45.7 | 40.5–134.9 | 0.250 | −29.0 | − 146.2-92.1 | 0.519 |